C91.92
Lymphoid leukemia, unspecified, in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Lymphoid leukemia, unspecified, in relapse (ICD-10 code C91.92), is a type of blood cancer that affects the lymphoid tissues and cells responsible for producing certain immune cells. When leukemia is in relapse, it means the disease has returned after a period of treatment or remission. This condition involves an uncontrolled growth of abnormal lymphoid cells in the blood and bone marrow, which can interfere with normal blood cell production and immune system function. Recognizing the signs and understanding the nature of this disease is essential for patients and caregivers navigating treatment pathways.
Causes & Symptoms
Clinical Causes: Genetic mutations affecting lymphoid cell development Previous chemotherapy or radiation therapy, which may contribute to genetic changes leading to leukemia Inherited genetic predispositions increasing susceptibility to blood cancers Exposure to certain chemicals or toxins, such as benzene Other environmental factors that may influence immune system functioning
Key Symptoms: Persistent fatigue or weakness Frequent infections or fever Unexplained weight loss Swollen lymph nodes, especially in the neck, armpits, or groin Easy bruising or bleeding Night sweats Bone or joint pain Loss of appetite Shortness of breath or dizziness in advanced cases
Diagnostic & Treatment
Diagnosis Path: Diagnosis of lymphoid leukemia in relapse involves a combination of laboratory and clinical assessments. Initial blood tests, such as complete blood count (CBC), can reveal abnormal lymphocyte levels. Bone marrow biopsy and aspiration provide definitive evidence of leukemia relapse and help determine the extent of disease. Imaging studies, like CT scans, may be used to evaluate internal lymph nodes or organs involved. Additional tests, such as immunophenotyping and genetic studies, help classify the leukemia subtype and inform treatment options.
Treatment Protocols: Chemotherapy regimens designed for relapsed leukemia, often more intensive than initial treatments Targeted therapy agents that attack specific genetic mutations or proteins involved in leukemia progression Immunotherapy to stimulate the body's immune system to fight the cancer cells Stem cell or bone marrow transplantation, especially in cases resistant to other therapies Supportive care to manage symptoms and reduce side effects, including transfusions and antibiotics
Clinical Advice & FAQs
Billing Guidance
Is C91.92 a billable ICD-10 code?
Yes, C91.92 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C91.92?
Clinical documentation must specify the nature of Lymphoid leukemia, unspecified, in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference